Can U.S. ensure access to a 2nd diagnostic test?

U.S. Rep. Debbie Wasserman Schultz, a Florida Democrat, is urging U.S. Patent and Trademark Office officials to license patents for confirmatory genetic tests, Genetic Engineering & Biotechnology News reports. During a recent agency hearing, she told officials the practice was necessary to ensure the best possible care for patients seeking a second opinion after cancer or other disease diagnoses. Opponents cited a U.S. Health and Human Services study that found, in part, that patients struggled to access genetic tests when the patent holders either delayed, chose not to develop or declined to license the technology for development elsewhere. The hearing is the first of two that will address the issue. Both are mandated by patent reform passed last fall, according to the article. Advocates and opponents await a study due in June that will recommend guidelines to ensure the availability of such tests. Story

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.